Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5833MR)

This product GTTS-WQ5833MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5833MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6586MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ6782MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ14120MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ12236MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ14603MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ5370MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ13042MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ9934MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW